Rinvoq (upadacitinib) / AbbVie - LARVOL DELTA

TREATMENT OF CHRONIC ERYTHEMA MULTIFORME USING JAK INHIBITORS: A SYSTEMATIC REVIEW (WRMC 2026) - "All patients were refractory to multiple systemic therapies, most commonly cyclosporine (58.3%), prednisone (50.0%), and valacyclovir (50.0%). JAK inhibitors, including tofacitinib and upadacitinib, demonstrated rapid and sustained disease control in chronic EM, including cases refractory to standard therapies. These findings support JAK inhibition as a promising therapeutic option for this challenging condition. Larger, prospective studies are warranted to confirm efficacy, optimize treatment duration, and assess the role of antiviral prophylaxis in herpes simplex virus– associated EM."

Review • Dermatology • Herpes Simplex • Inflammation

Late Development of Neurosarcoidosis on Adalimumab with Rapid Recurrence on a Biosimilar Agent (ACTRIMS Forum 2026) - "Ultimately, Amjevita was held, and he was treated acutely with pulse steroids followed by a long steroid taper...Most recently, he experienced recurrence of AS symptoms as was started on Upadacitinib, a JAK inhibitor... This case demonstrates that sarcoidosis can occur decades following the start of TNF⍺ therapy, much later than previously reported. Further, it supports the idea that rotation to a biosimilar molecule may be a trigger for paradoxical sarcoidosis in TNF⍺ therapy but also shows that rotation back to the original molecule may not be sufficient to avoid recurrence. Finally, it highlights the importance of exploration of other agents, including JAK inhibitors, for the treatment of NS when TNF⍺ inhibitors cannot be used."

Acute Kidney Injury • Ankylosing Spondylitis • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Nephrology • Renal Disease • Rheumatology • Sarcoidosis • Seronegative Spondyloarthropathies • Ulcerative Colitis

Major Adverse Cardiovascular Events and VTE in Patients with IBD Taking Anti-TNF versus JAK Inhibitors: A Multicenter Cohort Analysis. (PubMed, Dig Dis Sci) - "Our results suggest that patients with IBD, including patients ≥ 65 years, who are treated with JAKi, were not at increased risk of MACE or VTE over a 12-month period as compared to those treated with anti-TNF therapy. Further prospective studies are warranted to confirm these findings."

Adverse events • Journal • Cardiovascular • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • Venous Thromboembolism

Real-world Treatment Patterns of Biologics and Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis in the United States (AAAAI 2026) - "Non-mutually exclusive cohorts of AST users, including biologics (dupilumab, tralokinumab) and oral JAK inhibitors (JAKis; upadacitinib, abrocitinib), were defined by the first prescription (index date) between March 2017 and October 2024. Many switched from an AST to steroids and, if restarted, returned to their prior AST. These findings highlight the challenges of maintaining long-term disease control while on ASTs."

Clinical • HEOR • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team. (PubMed, Intest Res) - "Based on mechanistic, clinical, and real-world evidence, filgotinib may be a first-line option for patients with lower disease activity or when safety is a priority, whereas upadacitinib or tofacitinib may be preferred in higher disease activity. Strategically selecting agents may improve durability and outcomes."

Journal • Review • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Bowel Disease • Ulcerative Colitis • Varicella Zoster

Real-world effectiveness and safety of upadacitinib in Korean patients with inflammatory bowel disease: a single-center retrospective study. (PubMed, Intest Res) - "Upadacitinib was effective and well tolerated over 6 months in Korean patients with moderate-to-severe IBD, including those with biologic-experienced patients. These findings support its use in routine clinical practice, while highlighting the need for prospective studies to confirm its long-term safety and efficacy in Asian populations."

Journal • Real-world evidence • Retrospective data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Upadacitinib Rescue in Steroid- and Infliximab-Refractory Acute Severe Ulcerative Colitis: Remission in Half of Patients at 1 Year (ECCO-IBD 2026) - "Conclusion UPA appears to be a promising rescue option in patients with aASUC who fail intravenous steroids and IFX. In this highly refractory cohort, UPA induced rapid clinical and biochemical improvement, with approximately half of patients maintaining CR without colectomy for up to 1 year with an acceptable safety profile."

Clinical • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Association of endoscopic outcomes with long-term clinical improvements in patients with moderately to severely active Crohn’s disease treated with upadacitinib: Results from the U-ENDURE long-term extension study (ECCO-IBD 2026) - "CD-related hospitalisations or surgeries at LTE week 96, were significantly (nominal P ≤0.05) lower in pts with endoscopic remission and ulcer-free endoscopy at LTE week 0, and numerically lower in pts with endoscopic response. Conclusion A significantly higher proportion of pts who achieved endoscopic outcomes at 52 weeks and received up to 3 years of UPA maintenance treatment achieved long-term improvements in clinical and PROs and reduced CD-related hospitalisations or surgeries."

Clinical • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease

Real-World Effectiveness, Symptomatic Improvement, and Safety of Upadacitinib in Patients With Moderate-to-Severe Ulcerative Colitis: Interim Findings From the PROFUNDUS Study (ECCO-IBD 2026) - "Conclusion In the PROFUNDUS study, UPA-treated patients with UC achieved high rates of clinical and symptomatic improvement, regardless of AT status within an RW setting. Overall, UPA was well-tolerated, with few serious AEs observed, most of which were unrelated to UPA, as determined by the study investigator."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Effectiveness of JAK inhibitors in JAK naïve Ulcerative Colitis patients: Comparative analysis of tofacitinib, filgotinib and upadacitinib in the Dutch ICC Registry (ECCO-IBD 2026) - "Conclusion In this prospective real-world study, we compared TOFA, FIL and UPA treatment in JAK-naïve UC patients. The three treatments showed comparable CSFR rates and drug persistence, whereas UPA was associated with higher biochemical remission rates and more AEs."

Clinical • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CRP

Weighing up the evidence - JAK inhibitors do not cause drug-class specific gain of weight in Inflammatory Bowel Disease patients (ECCO-IBD 2026) - "Background The JAK inhibitors (JAKi) tofacitinib, filgotinib and upadacitinib are licensed in the UK for use in Inflammatory Bowel Disease (IBD) - upadacitinib in Crohn’s disease (CD), and all three in ulcerative colitis (UC)...1 We aimed to assess the effect of the drug class on weight in our population using JAKi by comparing to a matched cohort of those using infliximab (IFX)...Weight gain may reflect improvement in disease control, though the relationship between weight and disease activity in IBD is complex. With increased usage of JAKi for IBD, our findings may be of reassurance for clinicians and patients alike."

Clinical • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Off-label upadacitinib 60mg daily in the rescue of refractory Ulcerative Colitis: An open labelled cohort study (ECCO-IBD 2026) - "All had failed thiopurines and/or at least one other advanced therapy (infliximab: n=6, vedolizumab: n=6, adalimumab: n=1, ustekinumab: n=2, tulikisobart: n=1, tofacitinib: n=1, faecal microbiota transplant: n=1) and refused surgery. Conclusion We report the first case series of UPA 60mg daily demonstrating effectiveness in inducing remission after a median of 3.5 months in patients with refractory UC. UPA 60mg shows promise as a viable option of treatment escalation and appears safe, warranting further investigation into its long-term benefits."

Clinical • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Effectiveness and Safety of Upadacitinib in Patients with Crohn’s Disease and Ulcerative Colitis: a Korea Multicenter Retrospective Cohort Study (ECCO-IBD 2026) - "The safety profile was consistent with clinical trials, with no thromboembolic events or malignancies observed. These findings support UPA as an effective and well-tolerated therapeutic option for refractory IBD in routine practice.support UPA as an effective and well-tolerated therapeutic option for refractory IBD in routine practice."

Retrospective data • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Comparative Effectiveness of Upadacitinib vs Tofacitinib on Clinical Outcomes in Ulcerative Colitis: A Propensity-Matched Cohort Study (ECCO-IBD 2026) - "Although acute pancreatitis was included as a prespecified endpoint, no analyzable data were returned. These findings support upadacitinib as a potentially more effective option for reducing healthcare utilization in UC, warranting further comparative research."

Clinical • Clinical data • HEOR • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Long-term sustained improvement of health-related quality of life, work productivity and fatigue in patients with moderately to severely active Crohn’s disease treated with upadacitinib: Results from the U-ENDURE long-term extension study (ECCO-IBD 2026) - P3 | "Conclusion UPA (15 and 30 mg) maintenance treatment over a 3-year period was associated with sustained and clinically meaningful disease-specific and generic HRQoL improvement in patients with moderately to severely active CD. Despite the overall trend favouring UPA 30 mg, differences in patient-reported outcomes between the 2 dose groups were small."

Clinical • HEOR • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease

Androsterone Deficiency Sustains CXCL11 Macrophage Inflammation and Predicts Primary Non-Response to Ustekinumab in Crohn’s Disease (ECCO-IBD 2026) - "Additionally, we explored potential therapeutic strategies for UST non-responders to optimize personalized CD treatment, finding that switching to infliximab or upadacitinib yielded high rates of endoscopic and clinical improvement. We also revealed a metabolic–immune axis, mediated by the androsterone–AR–USP53–TAK1 pathway—that regulates UST efficacy in CD. These findings support the development of personalized treatment strategies and suggest viable alternatives for UST non-responders."

Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • CXCL11

From stress to healing: upadacitinib ameliorates epithelial endoplasmic reticulum stress and suppresses pro-fibrotic signalling in ulcerative colitis (ECCO-IBD 2026) - "When INF was used as a trigger, UPA upregulated TJP1 , a key marker of intestinal barrier restoration 3 , while in the ER exposed condition EIF2AK2 , an ER marker gene 4 , was downregulated by UPA (Fig.2C) . Conclusion Upadacitinib exerts context-dependent epithelial effects that extend beyond immunosuppression, directly enhancing epithelial resilience and tissue restoration."

Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • AKAP12 • IL1B • MFGE8 • MX1 • TJP1 • TNFA

Upadacitinib for the treatment of perianal Crohn’s disease: effectiveness and safety. A single centre real-world experience (ECCO-IBD 2026) - "Conclusion In this real-world single-centre cohort of highly refractory pCD, UPA achieved high and sustained CR and an acceptable safety profile. These findings support upadacitinib as a promising therapeutic option for complex pCD and highlight the need for prospective studies to define optimal dosing, duration, and radiological endpoints."

Clinical • Real-world • Real-world evidence • Crohn's disease • Immunology • Inflammatory Bowel Disease

Real-world outcomes of long-term upadacitinib 45mg maintenance therapy in inflammatory bowel disease: a single-centre retrospective cohort (ECCO-IBD 2026) - "Conclusion In this real-world IBD cohort, maintenance therapy with upadacitinib 45 mg was useful in achieving and maintaining remission in complex IBD patients with a favourable safety profile. These findings support the role of upadacitinib dose optimisation in selected population of IBD patients and underscore the need for prospective studies to define high-dose treatment duration and de-escalation strategies."

Real-world • Real-world evidence • Retrospective data • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Upadacitinib Induction and Maintenance Therapy in Crohn’ s Disease: A Retrospective Real-World Study in Biologic-Refractory Patients (ECCO-IBD 2026) - "Conclusion This real-world study demonstrates that upadacitinib is effective and generally well tolerated in biologic-experienced Chinese patients with active CD. Our findings support the clinical utility of JAK1 inhibition in a real-world setting."

Real-world • Real-world evidence • Retrospective data • Crohn's disease • Immunology • Inflammatory Bowel Disease • JAK1

Combining guselkumab with upadacitinib demonstrates efficacy in medically complex Crohn’s Disease (ECCO-IBD 2026) - "Conclusion Adding GUS to UPA in patients with medially complex CD resulted in a 30% clinical response rate and improvement of EIMs in 75% of affected patients. DTT with GUS should be considered in appropriate patients with CD who have evidence of active inflammation or EIMs despite monotherapy with UPA."

Clinical • Crohn's disease • Immunology • Inflammatory Bowel Disease

Real-world comparison of time to remission for upadacitinib vs other advanced therapies in patients with moderate-to-severe ulcerative colitis (ECCO-IBD 2026) - "Time to remission (defined as time from AT initiation to real-world clinical remission) for UPA vs other ATs, including anti–tumour necrosis factor inhibitors (TNFis), vedolizumab, ustekinumab and tofacitinib, was analysed using unadjusted Kaplan-Meier curves and significance was assessed using log-rank tests. Conclusion In a global, real-world setting, patients receiving UPA achieved clinical remission approximately 3 months faster compared to those receiving other ATs, highlighting the effectiveness of UPA treatment for moderate-to-severe UC. Faster remission may contribute to improved quality of life and reduced corticosteroid use or resource burden."

Clinical • Metastases • Real-world • Real-world evidence • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Real-world outcomes of upadacitinib therapy for patient with inflammatory bowel disease in Korea: A multicentre study (ECCO-IBD 2026) - "Acne was the most common adverse event (27.3%, 55.25/100 person-years), whereas serious adverse events were rare (Table 1). Conclusion UPA demonstrated favourable effectiveness and safety in Korean patients with IBD, with outcomes comparable to Western real-world data."

Clinical • Real-world • Real-world evidence • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Distinct fatigue trajectories in active IBD: clinical predictors and treatment-linked improvements independent of inflammation (ECCO-IBD 2026) - "Treatment with upadacitinib (p<0.001), infliximab (p<0.001) and vedolizumab (p<0.05) was associated with greater fatigue improvement, while risankizumab (p=0.07) and ustekinumab (p=0.15) was not, despite similar baseline levels of fatigue ( Figure 2B ). Improvement in fatigue was more strongly associated with specific advanced therapies and baseline mental health problems than baseline inflammatory markers. The differences between biologics classes are seen in a non-randomized setting and should lead to randomized controlled comparisons between interventions."

Clinical • Crohn's disease • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CRP

Safety Profile of Upadacitinib in Inflammatory Bowel Disease: Insights from FAERS Database and Single-Center Clinical Data Background (ECCO-IBD 2026) - "Background Upadacitinib, a selective JAK1 inhibitor, is approved for the treatment of ulcerative colitis and Crohn's disease. Discrepancies between FAERS and clinical data highlight the complementary roles of spontaneous reporting and active surveillance. Combination therapy with ustekinumab may increase the risk of neurological events, warranting further investigation."

Clinical data • Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis